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Stroke is the leading cause of neurological disability in the United States and worldwide. Remarkable advances have 
been made over the past 20 years in acute vascular treatments 
to reduce infarct size and improve neurological outcome. 
Substantially, less progress has been made in treatments to 
enhance neurological recovery after stroke. However, several 
promising research directions have been identified for treat-
ments targeting stroke recovery and are the focus of the cur-
rent review (Figure).
Epochs of time poststroke can be divided into acute 
(hours-days), subacute (days-weeks), and chronic (months-
years) based on the tissue response and biological programs 
that emerge during these time windows.1 In contrast to acute 
stroke treatments, such as tPA (tissue-type plasminogen acti-
vator) and thrombectomy, for which the target is a clot, and 
where the goal is to salvage threatened brain tissue to limit 
injury, recovery treatments target surviving neural tissue with 
the goal of promoting neural repair.
Recovery trials are thus fundamentally different from 
acute stroke trials.2 First, the time windows available for 
administering recovery-based treatments span much longer 
periods. These time windows enable detailed within-subject 
analyses before, during, and after treatment. Second, stroke 
deficits are multimodal (eg, combinations of motor, language, 
and other deficits) and recovery is modality-specific, meaning 
that different deficits recover with different rates and extents.3 
Accordingly, recovery trials often use modality-specific end 
points (such as the Fugl-Meyer [FM] Motor Scale), in addi-
tion to global outcome measures (such as the modified Rankin 
Scale [mRS] or the National Institutes of Health Stroke Scale 
[NIHSS]) that lump together all aspects of neurological func-
tion and are used in acute stroke trials. Third, recovery tri-
als have issues often not shared with other stroke research 
domains, such as variable standards of care, patient access and 
retention, difficulty with experimental blinding (particularly 
in the study of behavioral interventions), and importance of 
concomitant experiences4 (Table).
Spontaneous behavioral recovery occurs after stroke but 
is variable. The molecular and cellular mechanisms of this 
recovery have been extensively reviewed. Several treatment 
approaches in clinical translation aim to improve stroke re-
covery. Here, we review contemporary approaches to 
therapeutically enhancing stroke recovery, focusing on recent 
trials. For this review, we define stroke recovery treatments 
as nonvascular treatments initiated in the subacute to chronic 
phases (days to years) after stroke. Our intent is not to be 
comprehensive, but to highlight select examples of promising 
approaches and directions with an acknowledged emphasis on 
motor recovery. It should be noted that to date no small mol-
ecule or biologic has been approved by the Food and Drug 
Administration to promote stroke recovery.
Conventional Therapies
Conventional therapies for patients recovering from stroke in-
clude physical, occupational, and speech therapy. These are 
delivered across numerous care settings. The duration, inten-
sity, and type of conventional therapy are highly variable in 
the United States, complicating the design of control groups in 
stroke rehabilitation trials. Indeed, one of the research priori-
ties for stroke rehabilitation and recovery is better reporting 
and standardization of usual care in trials.1
Two specific interventions for stroke recovery with 
promising initial evidence emerging from conventional ther-
apies include mirror therapy and constraint-induced move-
ment therapy (CIMT).5 Mirror therapy, or prism adaptation 
therapy, uses simple equipment to focus a patient’s attention 
on a neglected hemifield. Mirror therapy, generally provided 
as an adjunct to conventional therapy, can improve motor 
function and reduce pain6 and might improve activities of 
daily living.7 Mirror therapy studies have been limited by 
small sample sizes and methodological limitations. Larger, 
more rigorous trials are needed. CIMT involves intensive 
rehabilitation therapy to overcome learned disuse by an af-
fected arm, with concomitant constraint of the unaffected 
arm. EXCITE (Extremity Constraint Induced Therapy 
Evaluation)8 was a phase 3 trial that found evidence that 
CIMT improved motor function, surpassing the minimally 
clinically important difference (MCID) in the Wolf Motor 
Function Test among patients in early chronic stroke. The 
timing of CIMT is important, as early application (10 days 
poststroke) was not more effective than traditional therapy.9 
Overall, there is moderate evidence that CIMT may be effec-
tive10 for poststroke recovery, but specific protocols and tim-
ing have yet to be defined for widespread clinical adoption.
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Small Molecules
The 2 classes of drugs that have been most investigated as 
stroke recovery treatments to date are serotonergic and do-
paminergic. Building on prior smaller studies, the FLAME 
study (Fluoxetine for Motor Recovery After Acute Ischemic 
Stroke) was a double-blind, placebo-controlled trial in which 
118 patients with weakness after ischemic stroke were ran-
domized to 3 months of oral fluoxetine or placebo, 5 to 10 days 
poststroke.11 Patients with clinical depression were excluded. 
Those randomized to fluoxetine showed significantly greater 
motor recovery to 90 days poststroke on the FM Motor Scale 
than those receiving placebo (a 9.8 point boost in recovery on 
the 100 point total FM for upper+lower extremities, largely 
driven by the upper extremity where fluoxetine-related gains 
exceeded the MCID of 5.25 points in chronic stroke12), as well 
as a significantly less disability as measured by the mRS; inter-
pretation is complicated by mild baseline imbalances favoring 
the fluoxetine group. A meta-analysis of 52 trials of selective 
serotonin reuptake inhibitors (SSRIs) after stroke found that 
at the end of treatment, patients receiving an SSRI were less 
likely to be dependent, disabled, neurologically impaired, de-
pressed, or anxious and that favorable effects were greater in 
participants who were depressed at randomization.13 Phase III 
trials examining SSRIs for stroke recovery are ongoing. Several 
mechanisms might account for the potential efficacy of SSRIs 
for stroke recovery, including reducing neural inflammation, 
enhancing neurotropic effects, and modulating excitatory/in-
hibitory synaptic and cortical network balance.14,15
Given their well-established role in reward, learning, and 
neural plasticity, dopaminergic drugs have also been investi-
gated for poststroke recovery. In 2001, a single-center (inpa-
tient rehabilitation facility), randomized, placebo-controlled 
study of 53 patients with ischemic stroke that occurred 3 
weeks to 6 months previously showed that a dopaminergic 
drug (Sinemet 100 mg/d) improved motor recovery measured 
using the Rivermead Motor Assessment.16 More recently, the 
Dopamine Augmented Rehabilitation in Stroke trial was a 
multicenter, randomized, double-blinded, placebo-controlled 
trial with some pragmatic design features that examined 
6 weeks of Sinemet 100 mg/d given before rehabilitation 
therapy in 593 patients recruited 5 to 42 days poststroke and 
found no difference between groups in the primary end point, 
walking independently.17 Overall, stroke recovery studies with 
dopaminergic drugs have been mixed, likely reflecting com-
plex interactions between learning, reward, environment, psy-
chology, cognition, and genetics.18 Stroke recovery is not a 
one-size-fits-all science, and so these results suggest the need 
to identify the optimal target population and conditions for 
therapies targeting dopaminergic neurotransmission.
Other small molecules, including noradrenergic19 and cho-
linergic20 drugs, have recently been explored for poststroke 
recovery. Amphetamines have been extensively studied, with 
Figure. Summary of current experimental treat-
ments for stroke recovery and their readiness 
for incorporation into clinical practice based 
on synthesis of current evidence. Readiness 
for clinical application ranges from preclinical 
development (ie, in animal studies only, red) to 
broad clinical application (green).
Table. Main Points
Stroke recovery trials target a different biology with a different time course as compared to acute stroke trials.
  Stroke recovery trials target brain tissue, not vasculature.
  Acute phase treatments (reperfusion, neuroprotection) have a time window measured in minutes and hours, whereas recovery treatments have time windows 
measured in days, week, months, or years.
  Recovery treatments are not targeted to rescue dying brain tissue but rather to promote neural repair in remaining tissue.
Many new promising strategies are on the horizon for stroke recovery.
Trials of treatments targeting stroke recovery benefit from employing modality-specific end points to obtain the granularity needed to measure differences in 
recovery across different neural systems (eg, recovery of language vs gait).
The time window for many recovery trials affords the opportunity to measure behavior at baseline and thus change in behavior, which in turn enables within-
subject assessment of recovery.
The choice of the study population for recovery studies can strongly influence how well preclinical results are accurately translated and how well study hypotheses 
are truly tested.
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mixed results, and a meta-analysis suggested that too few 
patients have been studied to draw conclusions.21 Building 
upon favorable preclinical studies,22 a phase IIa trial in France 
and Spain (https://www.clinicaltrials.gov; unique identifier: 
NCT02928393) of Basmisanil, a gamma-aminobutyric acid 
negative allosteric modulatory drug, was initiated but was ter-
minated prematurely after 9 months (enrollment was slow—
only 5 patients had been enrolled towards the goal of 95). A 
key insight from preclinical studies of neurotransmitter strate-
gies is that a drug that improves recovery when initiated days 
after stroke onset can cause poorer outcomes if initiated too 
early,22,23 reaffirming a longstanding observation in stroke re-
covery pharmacology that recovery drugs often have biphasic 
effects depending on time of initiation poststroke.
Few traditional and alternative medicines have been 
studied using formal research methods. One exception is 
the CHIMES study (Chinese Medicine Neuroaid Efficacy 
on Stroke Recovery),24 a multicenter, double-blind, placebo-
controlled clinical trial that randomized 1100 patients to 3 
months of Neuroaid versus placebo, provided in the form of 3 
daily doses of 4 oral capsules each. Neuroaid is a traditional 
Chinese medicine containing extracts of 9 herbal and 5 animal 
components. Patients started therapy within 72 hours of stroke 
onset. No difference between treatment arms was seen in the 
primary outcome measure, shift in the mRS at 3 months.
In summary, some small molecules are ready for late-
phase trials and indeed are underway, whereas others are in 
earlier stages of development or require study with respect to 
specific patient subgroups or conditions. Timing of drug initi-
ation is critical and can be informed by preclinical studies, as 
well as time window-finding studies in humans. Personalized 
medicine approaches can likely maximize benefit from small 
molecules for promoting stroke recovery, for example, enroll-
ing subjects with attention to key genetic factors or pairing 
drug exposure with optimized reward or training. Combining 
small molecules with appropriate repetitive neurorehabilita-
tion training may also be promising.
Growth Factors
After stroke, many growth factors show increased levels for 
several weeks, playing a critical role in spontaneous neural 
repair through mechanisms that include neural sprouting and 
new synapse formation, angiogenesis, reduced apoptosis, stem 
cell proliferation, and immunomodulation.25 One strategy to 
promote stroke recovery, therefore, is to increase levels of key 
growth factors.26 Numerous preclinical stroke studies suggest 
that administration of exogenous growth factors ≥24 hours 
poststroke significantly improves outcome, for example, using 
fibroblast growth factor,27 brain-derived neurotrophic factor,28 
epidermal growth factor plus erythropoietin,29 or beta-human 
chorionic gonadotropin (b-hCG) followed by erythropoietin.30
Systemic erythropoietin enters the brain and when intro-
duced with a delay after stroke (eg, ≈24 hours) can improve 
outcomes.31 Favorable effects of this growth factor have been 
described in other preclinical studies that used sequential admin-
istration of epidermal growth factor29 or b-hCG30 followed by 
erythropoietin, beginning 1 to 7 days after stroke. This approach 
was studied in the BETAS study (B-hCG+Erythropoietin 
in Acute Stroke), a single-dose, open-label, noncontrolled 
safety trial of b-hCG (initiated 1–2 days poststroke) followed 
by intravenous erythropoietin (initiated 7–8 days poststroke), 
which successfully demonstrated safety.32 The REGENESIS 
Study (Study of NTx™-265: Human Chorionic Gonadotropin 
[hCG] and Epoetin Alfa [EPO] in Acute Ischemic Stroke 
Patients)33 was intended to be a randomized, placebo-con-
trolled, double-blind proof of concept study of sequential 
b-hCG and erythropoietin using the BETAS study treatment 
schedule. This trial was put on hold because of concerns aris-
ing from a previous acute neuroprotection stroke trial34 that 
initiated erythropoietin <6 hours after stroke onset and found 
increased drug-related mortality rates, despite the fact that the 
REGENESIS trial targeted a different time window and biology 
(erythropoietin initiated <6 hours after stroke in the acute trial 
versus REGENESIS trial which waited until 7–8 days post-
stroke). As a result, the REGENESIS trial was modified to be a 
dose-ranging safety study, and treatment groups did not differ 
in NIHSS score change at day 90. Growth factors are likely ap-
propriate for further clinical study—development would benefit 
from clearer direction from preclinical studies for insights into 
mechanism of action (informing target human population), dos-
ing, and optimal timing.
Monoclonal Antibodies
In the central nervous system, 3 inhibitors (MAG [myelin-asso-
ciated glycoprotein], oligo-myelin glycoprotein, and neurite 
outgrowth inhibitor-A) increase levels poststroke and result in 
lack of a permissive growth environment.35 Monoclonal anti-
bodies can neutralize these inhibitors by modulating activity 
in targeted signaling pathways, thus promoting axonal growth 
and potential recovery. One study36 randomized 42 patients with 
stroke to 2 rounds (24–72 hours poststroke and 9 days later) of 
placebo versus 1 of 3 dose levels of intravenous GSK249320, 
a humanized IgG1 monoclonal antibody to MAG with disabled 
Fc region. No safety concerns were identified, and results sug-
gested that the antibody improved gait recovery. A subsequent 
phase II study37 compared the highest intravenous GSK249320 
dose level to placebo in 134 patients with stroke 24 to 72 hours 
prior.   Although administration of the antibody resulted in lower 
free serum MAG levels, the primary end point, change in gait 
velocity from baseline to day 90, did not differ between groups. 
Effective antibody activity was confirmed in the periphery but 
was not assessed in the central nervous system. In summary, 
monoclonal antibodies would benefit from further preclinical 
development followed by further early phase clinical study.
Cellular Therapy
Cell treatments have multiple effects in the poststroke brain. 
Transplanted cells might integrate into the existing brain archi-
tecture replacing cells lost to stroke; secrete cytokines, growth 
factors, and extracellular matrix proteins; or modify systemic 
immune responses to stroke aiding functional recovery. In a 
randomized, double-blind, placebo-controlled Phase 2 study, 
Hess et al38 delivered allogeneic marrow-derived cells intra-
venously to 126 patients early (24–48 hours) after ischemic 
stroke. Cell administration was safe, but no significant efficacy 
signal was seen in the primary end point: excellent outcome at 
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day 90 (mRS score 0–1, NIHSS score 0–1, and Barthel score 
≥95). Post hoc analysis at 1-year found a difference in excel-
lent outcome (23% cell-treated versus 8% placebo; P=0.02).
In a Phase 1/2 study, Kalladka et al39 stereotaxically 
implanted allogeneic immortalized human fetal neurons into 
the ipsilesional putamen adjacent to focal infarcts in 11 men 
with stable neurological deficits 6 to 60 months after ischemic 
stroke. There were 3 serious adverse events during the first 
month postprocedure: 2 asymptomatic intracranial hemato-
mas attributed to the procedure and 1 symptomatic infarct 
attributed to preprocedure suspension of antiplatelet drugs. 
Nonserious adverse events were mostly mild. Several patients 
showed treatment-related improvement, including on NIHSS, 
Ashworth scale, and Barthel Index.
In a single-arm, open-label study, Steinberg et al40 ste-
reotaxically implanted allogeneic modified marrow-derived 
mesenchymal cells into tissue surrounding focal infarcts in 
18 patients with stable deficits 6 to 60 months after ischemic 
stroke. Cell implantation appeared safe, with reversible ad-
verse events largely related to the surgical procedure. During 
1-year follow-up, significant improvements were seen in the 
European Stroke Scale, NIHSS, and FM scores, with no sig-
nificant changes in mRS.
In summary, early studies suggest that systemic and in-
tracranial cell administration is feasible and may prove safe 
and effective as treatments for promoting neurological re-
covery early and late after stroke. Optimal dose, route, and 
timing of cell administration remain underexplored. Further 
randomized, double-blind, placebo-controlled trials are 
needed and are ongoing.
Brain Stimulation
Several forms of brain stimulation have been investigated to 
enhance recovery after stroke, most in small studies. Some 
aim to increase activity, for example, with high-frequency re-
petitive transcranial magnetic stimulation,41 whereas others 
aim to reduce activity in areas thought to have an undesired 
suppressive effect, for example, with low-frequency repetitive 
transcranial magnetic stimulation.42 Similar approaches have 
been advanced for transcranial direct current stimulation,43 
where electrodes broadly apply current through the scalp in 
the treatment of several different types of poststroke deficits 
including motor, language, memory, and neglect. An advan-
tage of transcranial direct current stimulation is it is readily 
applied during rehabilitation. Meta-analyses have concluded 
that more evidence is needed to establish benefit.44,45 Two re-
cent studies showing positive effects of transcranial direct cur-
rent stimulation after stroke raise enthusiasm, one targeting 
dysphagia during the acute stroke hospitalization46 and the 
other targeting chronic aphasia.47 These highlight issues of 
capitalizing on anatomic substrates of neurological function 
(eg, bihemispheric control, for swallowing; unilateral domi-
nant hemisphere control, for language), as well as importance 
of considering timing of intervention poststroke.
Other approaches for brain stimulation are under study, 
including deep brain stimulation. A phase III trial did not find 
a significant benefit from epidural cortical stimulation com-
bined with rehabilitation compared with rehabilitation alone in 
patients with chronic stroke.48 Vagus nerve stimulation has been 
hypothesized to enhance brain plasticity, possibly by modulating 
activity in neurotransmitter systems, such as acetylcholine and 
norepinephrine.49 A recent randomized human clinical trial of 
vagal nerve stimulation paired with rehabilitation demonstrated 
safety and feasibility,50 and efficacy trials are ongoing.
To advance brain and nervous system stimulation for the 
treatment of stroke recovery, further clinical and possibly pre-
clinical studies (preclinical studies have been limited to date) 
are needed to inform mechanism, dose, intensity, and optimal 
targets to maximize effects.
Robotics
Robots are promising for stroke rehabilitation because they 
can deliver consistent, programmable, and high-intensity 
motor therapy, and furthermore can use sensors to measure 
movement kinematics. Numerous robotic systems have been 
studied.51 A 2010 multicenter study of 127 patients conducted 
within the Veterans Health Administration system showed that 
robot-assisted therapy did not significantly improve motor 
status at 12 weeks, the primary end point, as compared with 
usual care or intensive therapy. A delayed favorable effect as 
compared with usual care, however, was suggested in sec-
ondary analyses for 36 weeks.52 This study may have been lim-
ited by its choice of study population, enrolling patients with 
severe deficits in the chronic phase poststroke, among whom 
producing substantial benefits is challenging. Numerous other 
studies spanning different recovery stages for the past 20 years 
have demonstrated economic feasibility53 and therapeutic ben-
efits of robot therapy. Benefits of robot-assisted therapy for 
the upper extremity, however, are attributable to the intensity 
and repetition of movement practice,54 and robot-mediated 
therapy has not demonstrated clear additional benefits when 
compared with physical therapy when intensity and number 
of movement repetitions have been matched.55 Moreover, a re-
cent Cochrane review of robot-assisted and electromechanical 
arm training devices for improving arm function after stroke 
found only low-quality evidence that such interventions im-
prove activities of daily living.56
For the lower extremity, meta-analyses have shown that 
adding electromechanical-assistance (robot-assistance) to 
body weight support increases the odds of patients becoming 
independent with walking.57 However, a large clinical trial did 
not find body weight supported treadmill training to be su-
perior to progressive exercise at home managed by a phys-
ical therapist in patients 2-months poststroke.58 American 
Heart Association/American Stroke Association Guidelines 
describe Class IIb evidence supporting mechanically assisted 
walking with body weight support for patients who are non-
ambulatory after stroke.59
Overall, Phase 2 and possibly Phase 3 studies of robotics 
for stroke recovery are needed that enroll populations most 
likely to benefit or that test engineering approaches targeting 
improved functional outcomes using methods that build on 
the unique strengths of robots. Further development of robotic 
interventions might also include adjusting robot movements 
to patterns of disrupted movements and linking robot assis-
tance to cortical activity (ie, brain-computer interfaces [BCI]).
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Brain-Computer Interfaces
When a lesion is severe, one potential approach to restoring 
voluntary behavior is to capture signals from intact cortex 
and bypass the lesion. Some advocate a surgical approach. A 
recent study in patients with spastic arm paresis due to var-
ious diagnoses (25% were because of stroke), an average of 
15 years after the event showed that C7 nerve transfer from 
the nonparalyzed to paralyzed body side was associated with 
a 15 point increase in the FM arm score in the affected arm, 
exceeding the MCID for the upper extremity of 5.25 points 
in chronic stroke12 and with sustained improvements as com-
pared to controls (rehabilitation alone) at 1 year.60
An alternative approach to lesion bypass is a BCI. A BCI 
is a system that may or may not be noninvasive and that trans-
lates central nervous system signals into command signals 
for a technological device. The components of a BCI include 
devices for recording neural signals (sensors), the process of 
translating neural signals into command signals (neural decod-
ing), devices for executing command signals (effectors), and 
the feedback provided to the user (feedback). Using BCI sys-
tems, people with neurological disease have successfully con-
trolled computer cursors to regain communication and robotic 
prosthetics to restore movement.61 A complementary goal of 
BCI is to enhance rehabilitation therapy effects.62 The hypo-
thesis is that training patients to produce normal brain activity 
patterns through feedback reinforcement or linking neural ac-
tivity directly to sensory feedback of intended actions engages 
activity-dependent Hebbian neuroplasticity mechanisms and 
thereby restores native neurological functions. Initial studies in 
patients with chronic stroke have been promising, for example, 
electroencephalography-BCI training with an upper extremity 
orthosis produced a 3.4-point significant positive difference in 
the FM arm motor score compared with controls. Although shy 
of the MCID, behavioral gains in the experimental group cor-
related with adaptive changes in functional magnetic resonance 
imaging neural activity pattern, arguing that BCIs may induce 
clinically useful neuroplastic changes.63 Another recent study64 
showed that use of an electroencephalography-driven exoskel-
eton to open and close the affected hand using signals from the 
contralesional (unaffected) hemisphere significantly improved 
arm function (6.2 point increase on the Action Research Arm 
Test score, exceeding the 5.7 point MCID65 in chronic stroke). 
This study was notable given the use of signals from the unaf-
fected hemisphere and delivery of therapy at home. Advances in 
BCI will benefit from a deeper understanding of how to facilitate 
personalized neural signals to enhance neuroplasticity, as well 
as a more nuanced understanding of circuit function in spon-
taneous recovery after stroke. More generally, the paradigm of 
closed-loop neurotechnological devices, in which sensing neural 
activity is coupled with effecting change in the nervous system, 
is a promising neurorehabilitation approach. Further preclinical 
study and early phase clinical development are needed.
Telerehabilitation
Task-based practice improves outcomes after stroke in a dose-
dependent manner and also provides the behavioral compo-
nent of the experience-dependent plasticity that is facilitated 
by many restorative therapies. However, patients often do not 
receive large doses of supervised practice because of issues 
such as cost, difficulty traveling to appointments, and regional 
provider shortages. Telehealth might provide new means to 
achieve high doses of therapy in an accessible manner using 
communication technologies. One recent study evaluated a 
home-based telerehabilitation system in patients with chronic 
hemiparetic stroke with onset 3 to 24 months prior.66 Enrollees 
received 28-days of telerehabilitation prescribed and super-
vised by licensed therapists using a system delivered to the 
patient’s home, each day consisting of 1 structured hour fo-
cused on individualized exercises and games, stroke educa-
tion, plus an hour of free play. Compliance was excellent: 
participants engaged in therapy on 97.9% of assigned days, a 
substantial improvement over traditional home exercise pro-
grams. Arm repetitions averaged 879 per day, far exceeding 
the 32 repetitions found with standard of care therapy67 and 
approximating the several hundred movements per day found 
in primate studies as important to achieving optimal post-
stroke motor cortex plasticity.68 Arm motor status showed sig-
nificant gains, with half of the participants exceeding the arm 
motor FM score MCID. This approach did not require com-
puter skills, levels of which were unrelated to motor gains or 
system use. A multisite phase II trial is now underway (https://
www.clinicaltrials.gov; unique identifier: NCT02360488). 
Meta-analyses of telerehabilitation after stroke have found 
either better or similar effects when compared with conven-
tional in-person therapy but have noted high heterogeneity in 
treatment content across studies.69,70 Further clinical develop-
ment of telerehabilitation to optimize dose and standardize 
protocols is warranted before late-phase clinical trials.
Virtual Reality and Movement Sensors
There is converging evidence that high-dose, repetitive, task-ori-
ented, and task-specific training is beneficial, at least for selected 
patients after stroke.71,72 The key is not simply a greater number 
of repetitions but also task salience and specific attention to time 
poststroke and external environment.73–76 Virtual reality (VR), 
ranging from nonimmersive to fully-immersive depending on 
the degree to which the user is isolated from his or her phys-
ical surroundings when interacting virtually, has been used as 
an alternative and as an adjunct to conventional rehabilitation. 
VR provides a scalable means to deliver high-intensity, task-
specific training, as well as real-time feedback (ie, rewards for 
positive trials) potentially with enhanced salience. However, the 
evidence for efficacy of VR to date has been mixed.77–80 Well-
designed studies that build on prior work are needed, possibly 
maximizing salience to individual patient factors.
Movement sensors are another means of providing feed-
back with the goal of motivating greater skills practice and thus 
improving rehabilitation. In this regard, lower extremity sen-
sors providing simple measures of physical activity and gait 
are more developed than upper extremity sensors, for which 
accurately characterizing reaching and grasping movements 
represents an ongoing computational challenge.81 In one lower 
extremity sensor feasibility study, participants were given feed-
back of walking metrics via ankle sensors. This augmented 
feedback did not increase time spent practicing or improve 
walking outcomes in a rehabilitation setting as compared to 
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therapists providing feedback on walking speed alone (without 
the use of ankle sensors).82 A recent review found some ev-
idence that lower extremity wearable sensors improved out-
comes, but the design of studies included was highly variable.83 
As with VR, additional earlier phase studies are needed, partic-
ularly those building on principles of personalized intervention.
Summary and Future Directions
This review highlighted contemporary treatment approaches 
aimed at improving recovery after stroke. Development of stroke 
recovery treatments will depend on increased understanding of 
the complex events underlying recovery and development of 
methods to measure treatment effects in human patients. A key 
issue is optimal treatment timing, as specific critical periods for 
most interventions have not yet been defined. Trial design is also 
paramount, for example, end points targeting a single domain 
(motor, language, etc) may be more informative than global 
outcome measures that combine data from multiple different 
domains. Outcome measures benefit from having sufficient 
granularity to detect useful functional gains and being informa-
tive about the biology of recovery—global outcome measures, 
such as the mRS, may have critical shortcomings in this regard. 
As the efficacy and mechanism of individual treatments target-
ing stroke recovery are better understood, combinations of ex-
isting and novel therapies will warrant investigation.
Stroke recovery trials offer the opportunity for rigorous 
testing, for example, at baseline as entry criteria or stratifi-
cation variables. Serum, genetic, imaging, and neurophysi-
ologic data may be useful as predictors.84 For example, motor 
response to transcranial magnetic stimulation85 differentiates 
patients likely to experience spontaneous motor recovery from 
those who will not. An imaging-based measure of corticospi-
nal tract injury can prospectively identify responders to reha-
bilitation therapy in chronic stroke.86 Some of these measures 
can be serially collected as biomarkers of treatment effect.
The field of stroke recovery continues to benefit from the 
combination of perspectives of clinicians caring for stroke 
patients, as well as the scientists elucidating biological mech-
anisms of recovery and developing new recovery-promoting 
technologies. These groups bring invaluable insights.
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